For instance, DDRis, namely PARP inhibitors (PARPi) [18] and checkpoint kinase 1 (CHK1) inhibitor [19], have predominantly been studied in patients with breast or ovarian cancers. This evidence concerns the gene CHEK1 and ovarian carcinoma.